683 Capital Management’s Cue Biopharma CUE Stock Holding History

683 Capital Management’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-24,792	Closed	-$10.8M	–	350
2021 Q3	$10.8M	Buy	24,792 +1,318	+6%	+$460K	0.42%	55
2021 Q2	$8.2M	Buy	23,474 +12,226	+109%	+$4.74M	0.28%	70
2021 Q1	$4.12M	Buy	11,248 +581	+5%	+$239K	0.22%	76
2020 Q4	$4M	Hold	10,667	–	–	0.19%	78
2020 Q3	$4.82M	Hold	10,667	–	–	0.35%	53
2020 Q2	$7.84M	Hold	10,667	–	–	0.63%	40
2020 Q1	$4.54M	Hold	10,667	–	–	0.53%	45
2019 Q4	$5.08M	Buy	10,667 +667	+7%	+$210K	0.58%	43
2019 Q3	$2.53M	Buy	+10,000	New	+$2.4M	0.28%	57

Other funds holding CUE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

683 Capital Management's CUE Position: Q4 2021 in Review

683 Capital Management sold out of Cue Biopharma (CUE) in Q4 2021, closing a stake of 24,792 shares — an estimated $10.8M sold.

683 Capital Management first reported a position in CUE in Q3 2019 and held it in 9 quarters. The position peaked at $10.8M in Q3 2021. 90 funds tracked by Wall St. Rank hold CUE as of Q4 2021.

683 Capital Management reported no remaining Cue Biopharma position as of Q4 2021 after selling out during the quarter.
683 Capital Management sold 24,792 Cue Biopharma shares in Q4 2021, an estimated $10.8M.
683 Capital Management first reported a position in Cue Biopharma in Q3 2019 and held it in 9 quarters.
683 Capital Management's Cue Biopharma position peaked at $10.8M in Q3 2021.
90 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2021.

Based on 683 Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.